Market access in pharma

The topic of market access in Pharma will be explored by highlighting its importance in bridging innovation and patient access. We will differentiate between regulatory approval and reimbursement, explaining the unique roles each plays in patient access to new therapies. The lecture will discuss challenges in securing reimbursement across various healthcare systems and the central role of health economic evaluations and tailored strategies in ensuring successful market access. In the pharmaceutical industry, market access serves as the gateway between innovation and real world impact. It includes all activities needed to ensure patients receive new medicines, not only after regulatory approval, but also through the process of making treatments available and affordable. True market access is achieved when payers, such as National Health Systems or insurers agree to reimburse the therapy. Understanding both regulatory and reimbursement complexities is key to broad equitable access. It is crucial to distinguish between regulatory approval and reimbursement, as both play unique roles in pharmaceutical market access. Regulatory agencies like the FDA, EMA, or MHRA assess new medicines based on safety, efficacy, and quality, granting the right to market, but not ensuring payment by health systems or insurers. Reimbursement is decided by payers who consider the medicine's value, cost effectiveness, and local healthcare priorities. Navigating both processes is